| Patents for A61K 38 - Medicinal preparations containing peptides (316,240) |
|---|
| 07/23/2009 | WO2009090648A2 Use of antimicrobial polymers for re-sensitization of microorganisms upon emergence of resistance to anti-microbial agents |
| 07/23/2009 | WO2009090330A2 Use of protein 8c2 for in vitro diagnosis of mycoplasma pneumoniae infections |
| 07/23/2009 | WO2009090287A1 Cirp-based antitumour compounds |
| 07/23/2009 | WO2009090227A2 PEPTIDES HAVING BINDING AFFINITY TO AN ANTIBODY WHICH RECOGNIZES AN EPITOPE ON AN α1 LOOP 2 OR β2 LOOP 1 OF AN ADRENORECEPTOR |
| 07/23/2009 | WO2009090189A1 Powdered protein compositions and methods of making same |
| 07/23/2009 | WO2009090168A1 Anti-bacterial compositions |
| 07/23/2009 | WO2009090049A1 Peptides for the specific binding and regulation of protein targets |
| 07/23/2009 | WO2009089858A1 COMBINATION OF AN ANTI-EDb FIBRONECTIN ANTIBODY-IL-2 FUSION PROTEIN, AND A MOLECULE BINDING TO B CELLS, B CELL PROGENITORS AND/OR THEIR CANCEROUS COUNTERPART |
| 07/23/2009 | WO2009089678A1 Scirr10 neurotrophic factor, its receptor and uses thereof |
| 07/23/2009 | WO2009089635A1 Treating neurodegenerative diseases with progranulin (pgrn) |
| 07/23/2009 | WO2009089620A1 Protein c rs2069915 as a response predictor to survival and administration of activated protein c or protein c-like compound |
| 07/23/2009 | WO2009073648A3 Compositions and methods for regulating entamoeba histolytica function |
| 07/23/2009 | WO2009072119A3 Amphiphilic peptide matrices for treatment of osteoporosis |
| 07/23/2009 | WO2009071680A3 Rna antagonist compounds for the modulation of mcl-1 |
| 07/23/2009 | WO2009067690A3 Methods for safe and effective treatment using oxazaphosphorine drugs |
| 07/23/2009 | WO2009059309A3 Furin-cleavable peptide linkers for drug-ligand conjugates |
| 07/23/2009 | WO2009058734A4 Compounds exhibiting glucagon antagonist and glp-1 agonist activity |
| 07/23/2009 | WO2009053535A3 Peptide vaccine for influenza virus |
| 07/23/2009 | WO2009052379A3 Improved antitumoral treatments |
| 07/23/2009 | WO2009048658A3 Optimized dengue virus entry inhibitory peptide (dn81) |
| 07/23/2009 | WO2009046845A3 Use of a lactoferrin partial peptide peptide as a therapeutic agent |
| 07/23/2009 | WO2009043523A3 Cortistatin 17 and neuropeptide 1 for use as therapeutic agent |
| 07/23/2009 | WO2009040084A3 Use of a peptide as a therapeutic agent |
| 07/23/2009 | WO2009040034A3 Use of a peptide as a therapeutic agent |
| 07/23/2009 | WO2009039973A3 Use of peptide arg-asn-ile-ala-glu-ile-ile-lys-asp-ile-oh or its combination with the peptide asp-arg-gly-asp-ser-oh as a therapeutic agent |
| 07/23/2009 | WO2009039971A3 Use of the peptide sfllr-oh and muramyl dipeptide as therapeutic agents |
| 07/23/2009 | WO2009033816A3 Use of the combination of thymosin beta 10 and thymosin alpha 1 peptides as a therapeutic agent |
| 07/23/2009 | WO2009033773A3 Use endothelin 2, alone or combined with a nonapeptide, a peptide as a therapeutic agent |
| 07/23/2009 | WO2009033761A3 Use of a fragment of hcv nucleo protein, alone or together with endothelin-3, as a therapeutic agent |
| 07/23/2009 | WO2009027063A3 MUTANT DOUBLE CYCLIZED RECEPTOR PEPTIDES INHIBITING β1-ADRENOCEPTOR ANTIBODIES |
| 07/23/2009 | WO2009019604A3 Delivery systems for solubilising water-insoluble pharmaceutical active ingredients |
| 07/23/2009 | WO2009015063A8 Methods and compositions for treating fibrosis related disorders using il-17 antagonists |
| 07/23/2009 | WO2009009782A9 Cynomolgus il-17 proteins, antibodies, compositions, methods and uses |
| 07/23/2009 | WO2008153762A3 S-nitrosothiol formulations and storage systems |
| 07/23/2009 | WO2008142693A8 Regulation of myelination by nectin-like (necl) molecules |
| 07/23/2009 | WO2008103043A8 Rgd containing recombinant gelatin |
| 07/23/2009 | WO2008103042A8 Recombinant xrgd-enriched gelatins having high stability |
| 07/23/2009 | WO2008103041A8 Recombinant gelatins |
| 07/23/2009 | WO2008063113A8 Cell -penetrating peptides and constructs containing them consisting 15-25 amino acids of tumor supressor protein p14arf or p19arf |
| 07/23/2009 | WO2008001342A8 Recombinant staphylococcal phage lysin as an antibacterial agent |
| 07/23/2009 | WO2007147014A8 Method and systems for using biopolymer-based beads and hydrogels |
| 07/23/2009 | WO2007145589A8 Peptides that are capable of binding to amyloid-beta peptide. |
| 07/23/2009 | WO2007137303A8 Permeability of blood-brain barrier |
| 07/23/2009 | WO2007133153A8 Improved antimicrobial peptides |
| 07/23/2009 | WO2007126364A8 Use of antisecretory factors for treating intraocular hypertension |
| 07/23/2009 | WO2007126363A8 Antisecretory protein for use in the treatment of compartment syndrome |
| 07/23/2009 | WO2007125142A8 Antimicrobial linear peptides |
| 07/23/2009 | WO2007109648A8 Compositions and methods for modulating store-operated calcium entry |
| 07/23/2009 | WO2007100248A4 Adir related polymorphisms and applications thereof |
| 07/23/2009 | WO2007096854A8 Compositions and methods for modulating an immune response |
| 07/23/2009 | WO2007091958A8 Novel antimicrobial peptides and use thereof |
| 07/23/2009 | WO2007090022A8 Novel compounds for targeting endothelial cells, compositions containing the same and methods for their use |
| 07/23/2009 | WO2007086093A8 Inhibitors of cell migration mediated by h-prune-gsk-3 complex and uses in antitumoral therapy |
| 07/23/2009 | WO2005056752A9 Methods and compositions for delivering polynucleotides |
| 07/23/2009 | US20090188000 Gene family (lbfl313) associated with pancreatic cancer |
| 07/23/2009 | US20090186945 Abuse-resistant amphetamine prodrugs |
| 07/23/2009 | US20090186908 Use of 3-hydroxy-3-methylglutaryl coenzym a reductase inhibitors for the manufacture of a medicament for the treatment of diabetic neuropathy |
| 07/23/2009 | US20090186867 Substituted Diketopiperazines As Oxytocin Antagonists |
| 07/23/2009 | US20090186846 Methods to reprogram splice site selection in pre-messenger RNAs |
| 07/23/2009 | US20090186845 Interfering rna molecules |
| 07/23/2009 | US20090186843 RNA sequence-specific mediators of RNA interference |
| 07/23/2009 | US20090186832 Amino acid peptide pro-drugs of phenolic analgesics and uses thereof |
| 07/23/2009 | US20090186831 Tetrahydrofuro(3,2-B) pyrrol-3-one derivatives as inhibitors of cysteine proteinases |
| 07/23/2009 | US20090186830 Macrocycles and their uses |
| 07/23/2009 | US20090186829 Nitrosation-Inducible Inhibitors Biological Macromolecules |
| 07/23/2009 | US20090186828 Abuse-resistant amphetamine prodrugs |
| 07/23/2009 | US20090186827 Process of inhibiting cell death in injured cartilage |
| 07/23/2009 | US20090186825 Abuse-resistant amphetamine prodrugs |
| 07/23/2009 | US20090186824 Novel peptides for treating and preventing immune-related disorders, including treating and preventing infection by modulating innate immunity |
| 07/23/2009 | US20090186823 Synthetic arginine substituted peptides and their use |
| 07/23/2009 | US20090186822 Thrombopoietic Compounds |
| 07/23/2009 | US20090186821 Use of aspartic proteases in cosmetics and therapeutics |
| 07/23/2009 | US20090186820 Streptococcus pyogenes polypeptides and corresponding dna fragments |
| 07/23/2009 | US20090186819 Formulation of insulinotropic peptide conjugates |
| 07/23/2009 | US20090186818 Therapeutic Method for Glycaemic Control |
| 07/23/2009 | US20090186817 Peptide-peptidase inhibitor conjugates and methods of using same |
| 07/23/2009 | US20090186816 Polypeptide targeting to mitochondria |
| 07/23/2009 | US20090186815 Identification of jak/stat pathway modulating genes by genome wide rnai screening |
| 07/23/2009 | US20090186814 Methods and Compositions for Reducing Ischemia-Derived Microvascular Damage |
| 07/23/2009 | US20090186813 Chronic treatment regimen using glucagon-like insulinotropic peptides |
| 07/23/2009 | US20090186812 Apo-2 ligand |
| 07/23/2009 | US20090186811 Y2 Selective Receptor Agonists for Therapeutic Interventions |
| 07/23/2009 | US20090186810 Potassium channel modulators and platelet procoagulant activity |
| 07/23/2009 | US20090186809 Use of valproic acid for the topical treatment of mild to moderate acne vulgaris |
| 07/23/2009 | US20090186808 Method and Compound for the Treatment of Valvular Disease |
| 07/23/2009 | US20090186807 Zinc-free and low-zinc insulin preparations having improved stability |
| 07/23/2009 | US20090186806 Truncated Activin Type II Receptor and Methods of Use |
| 07/23/2009 | US20090186805 Compositions and Methods for Genetic Modification of Cells Having Cosmetic Function to Enhance Cosmetic Appearance |
| 07/23/2009 | US20090186804 Anticoagulant and composition for preventing thrombus containing poly-gamma-glutamic acid |
| 07/23/2009 | US20090186803 Use of nutritional compositions with phospholipid, sphingolipid and cholesterol. |
| 07/23/2009 | US20090186802 Cell Penetrating Peptide Conjugates for Delivering of Nucleic Acids into a Cell |
| 07/23/2009 | US20090186801 Methods of Inhibiting Tumor Cell Aggressiveness Using The Microenvironment of Human Embryonic Stem Cells |
| 07/23/2009 | US20090186422 Peptide for use in the treatment of immunological defects and allergies; capable of inhibiting protein-protein interaction between calcineurin and NFAT |
| 07/23/2009 | US20090186376 sVEGFR-2 AND ITS ROLE IN LYMPHANGIOGENESIS MODULATION |
| 07/23/2009 | US20090186363 Compositions and methods for the diagnosis and treatment of tumor |
| 07/23/2009 | US20090186338 Oligonucleotides originating from sequences coding for the surface component of ptlv envelope proteins and their uses |
| 07/23/2009 | US20090186337 N protein of a virus of the paramyxoviridae family-protein of interest fusion proteins |
| 07/23/2009 | US20090186099 Buccal, polar and non-polar spray or capsule containing drugs for treating disorders of the central nervous system |
| 07/23/2009 | US20090186098 Sports drink composition |
| 07/23/2009 | US20090186075 Composition |